Breast Cancer Evolution During Neoadjuvant Systemic Therapy
Recruiting · NCT06681064 · Observational (researchers observe without assigning treatment)
View the official record on ClinicalTrials.gov →What this trial is about
BELIEVE is a translational research study that aims to collect samples of breast cancer tissue and blood from individuals undergoing breast cancer treatment (such as chemotherapy, targeted therapy and immunotherapy) before surgery. In certain cases, MRI scans and stool samples will also be obtained before and during treatment. The samples collected from this study will be used for molecular and genetic research to understand why some cancers respond very well to anticancer treatments, and some do not, develop novel ways of accurately measuring response during treatment, as well as identify which patients are at a higher risk of the cancer coming back after surgery.
Who can take part
Inclusion criteria
- Histologically confirmed non-metastatic invasive breast cancer.
- Be suitable for, but have not commenced, neoadjuvant chemotherapy, targeted therapy, or immunotherapy.
- If HER2-, suitable for treatment with upfront taxane chemotherapy. If HER2+, suitable for treatment with anti-HER2 targeted therapy.
- Be aged 18 years and over.
- Have given written informed consent to participate.
Exclusion criteria
- Metastatic breast cancer at diagnosis.
- Treatment with neoadjuvant endocrine therapy only.
- Presence of any psychological, familial or sociological condition potentially hampering compliance with the study protocol and follow-up schedule.
Where it is running
1 location listed.
- Royal Marsden NHS Foundation Trust - London, United Kingdom